At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...

Kidney cancer is not exclusively a disease of older patients. For many young adults, the diagnosis comes as a shock, often appearing without warning in those who otherwise feel healthy.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and ...

Mehra added that research in head and neck cancer is entering an exciting phase, with growing interest in bispecific antibodies targeting EGFR. With newer dual-targeting agents, including Rybrevant, ...

Director of Head and Neck Oncology in the Division of Hematology/Oncology and associate director for Clinical Research at the University of Maryland School of Medicine.

Developing assertiveness is portrayed as a protective shift from people-pleasing and emotional suppression toward clearer ...

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future. Recently, the U.S. Food and Drug Administration (FDA) accepted ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...

The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...